Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.

Sondak VK, Sosman JA
Semin Cancer Biol. 2003 13 (6): 409-15

PMID: 15001159 · DOI:10.1016/j.semcancer.2003.09.004

The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX. Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting. A phase III trial indicated a survival benefit for Melacine in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed.

MeSH Terms (9)

Cancer Vaccines Clinical Trials as Topic HLA Antigens Humans Immunotherapy, Active Melanoma Neoplasm Staging Skin Neoplasms Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: